A bioassay of @entity69591 , a plant growth regulator, for possible carcinogenicity was conducted by administering the test chemical in the diet to Fischer 344 @entity35 and B6C3F1 @entity19 . Groups of 50 @entity35 and 50 @entity19 of each sex were administered @entity69591 at one of two doses, either 5,000 or 10,000 ppm, for 104 weeks, then observed for an additional week. Matched controls consisted of 20 untreated males and 20 untreated females of each species. All surviving @entity35 and @entity19 were killed at 105 weeks. Mean body weights of the high-dose female @entity19 were appreciably lower than those of the corresponding controls, while mean body weights of all other dosed groups of @entity35 and @entity19 were essentially unaffected. No other clinical signs related to administration of @entity69591 were observed. Sufficient numbers of animals in all groups of @entity35 and @entity19 were at risk for development of late-appearing @entity5 . In the male @entity35 , no @entity5 occurred at incidences that were significantly higher in dosed groups than in controls, except for @entity8302 of the @entity1062 (controls 13/20, low-dose 49/50, high-dose 47/50). These @entity5 occurred, however, at a high spontaneous rate (182/220) in the historical-control male @entity35 ; thus, the association of the @entity8302 with administration of the chemical is doubtful. In the female @entity35 , @entity420 of the endometrium and @entity1822 of the uterus occurred only in the dosed groups ( @entity420 : controls 0/19, low-dose 5/50, high-dose 3/50; @entity1822 : controls 0/19, low-dose 1/50, high-dose 3/50). The incidences in the dosed groups were too low to be statistically significant; however, the low incidence of these @entity5 in historical-control female @entity35 (2/220 @entity420 ) indicate that the occurrence of these @entity5 in the dosed female @entity35 was associated with the administration of @entity69591 . In the male @entity19 , there was a dose-related trend (P=0.008) in the incidence of @entity157 ; also, the incidence in the high-dose group was significant (P=0.020) compared with that in the controls (controls 0/14, low-dose 7/50, high-dose 13/46). The incidence of these @entity5 in the historical-control male @entity19 was, however, 21/216; thus, the association of the @entity157 with administration of @entity69591 is not clear. In female @entity19 , only three such @entity5 occurred. It is concluded that under the conditions of this bioassay, @entity69591 was not carcinogenic in the male Fischer 344 @entity35 or in the female B6C3F1 @entity19 . In male B6C3F1 @entity19 , the induction of @entity157 may have been associated with the administration of the test chemical. @entity69591 was carcinogenic in female Fischer 344 @entity35 , inducing @entity420 of the uterus.

Bioassay of XXXX for possible carcinogenicity.

@entity19 :: ('10090', 'Species') :: ['mice'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumors'] @entity1822 :: ('MESH:D007890', 'Disease') :: ['leiomyosarcomas'] @entity8302 :: ('MESH:D007984', 'Disease') :: ['interstitial-cell tumors'] @entity157 :: ('MESH:D006528', 'Disease') :: ['hepatocellular carcinomas'] @entity1062 :: ('MESH:D013736', 'Disease') :: ['testis'] @entity35 :: ('10116', 'Species') :: ['rats'] @entity69591 :: ('MESH:C014499', 'Chemical') :: ['daminozide', 'Daminozide'] @entity420 :: ('MESH:D000230', 'Disease') :: ['adenocarcinomas', 'adenocarcinoma and 0/220 leiomyosarcoma', 'adenocarcinomas of the endometrium of the uterus and leiomyosarcomas']
@entity69591 :: (MESH:C014499,Chemical) :: ['daminozide']
